A systemically injectable peptide, which may make it possible to restore lost functions in spinal cord injury patients, is moving toward clinical trials in early 2020, BioSpace reports.
The treatment was developed by Dr Jerry Silver, a professor of neurosciences at Case Western Reserve University’s School of Medicine and advisor for NervGen Pharma.
It’s the culmination of decades of work, and in pre-clinical studies, it has shown robust results in animal models.
Read the full media release here.
In-depth: Dr Jerry Silver – Spinal cord damage and emerging treatments